I connect capital, startups, and corporates across consumer health — turning market insight into revenue, strategic partnerships, investments, and exits.
Consumer health is moving fast. Capital, startups, and corporates still struggle to connect in a way that creates real commercial outcomes.
Need better deal flow — vetted, on-thesis, with operator diligence already done.
Need access and revenue — the right corporate decision-makers, not more outreach noise.
Need startups that actually deliver ROI — pilots that scale into procurement, not innovation theatre.
I operate between these three worlds — and turn access into execution.
Curated, operator-vetted consumer health opportunities for family offices, syndicates, and funds.
Request deal flow → For Startups 02Direct routes between startups and corporates — structured for revenue, not press releases.
Build your pipeline → For Corporates 03I help corporates quickly source and onboard startups that grow revenue — pilots and partnerships built around real P&L use cases, not innovation theatre.
Source startups →Fourteen years inside Big Pharma, Consumer Health corporates and AI-native scale-ups — CEO, CBDO, venture builder and C-level seats across six countries. The judgment to assess opportunities and the network to create them.
Operator history inside Merck · Johnson & Johnson · Unilever · Valenta · Askona Life.
Most deal flow is either too broad, too early, or poorly validated. I provide curated consumer health opportunities and operator-led commercial diligence for investors actively deploying capital into consumer health.
For: Family Offices · Angel Syndicates · VC Funds · Impact Investors · UHNW direct investors
Family offices, angel investors, and funds looking for direct investments, co-investments, or thesis-driven exposure to consumer health.
Outcome: Better deals. Lower risk. Faster decisions.
Great products often fail to scale because founders cannot reach the right corporate decision-makers. I build the narrative, identify the right targets, open conversations, and support deal execution.
For: Seed–Series B consumer health, HealthTech, wellness, beauty tech, AI health, longevity, diagnostics & digital health
Series A/B startups with real traction — revenue, pilots, or live corporate signals.
Outcome: More qualified conversations. Stronger partnerships. Better strategic options.
Corporate innovation often fails because startup scouting is disconnected from commercial priorities. I identify, assess, and structure startup partnerships around real business use cases.
For: Pharma · Consumer Health · Diagnostics · Beauty · Wellness · FMCG · Insurance · Retail · Healthcare Services
Corporates with clear innovation or growth priorities and a budget owner ready to act.
Outcome: Faster innovation. Better pilots. Clearer ROI.
Define the market, targets, and commercial objective. Sharp scope before activity.
Create a clear deal, partnership, or investment story — tuned to the audience that has to say yes.
Targeted introductions to investors, founders, corporates, and decision-makers. Warm, specific, and relevant.
Move conversations toward pilots, contracts, investments, or strategic partnerships — with the operator pressure to close.
I work selectively. Each engagement is scoped against a specific commercial outcome.
Market mapping, opportunity validation, investor or corporate target lists, partnership narrative.
Fit: a clear thesis to pressure-test or a defined audience to reach.
Live deal flow, BD execution, strategic partnerships, investor and corporate pipeline building.
Fit: a sustained mandate where access compounds over time.
Compensation can include success fees tied to introductions, partnerships, investments, or commercial outcomes.
Fit: defined deals where outcomes — not hours — are the unit of work.
Active categories where I am seeing the strongest commercial activity, deal flow, and corporate appetite right now.
I work best with partners who already have capital, product traction, or a corporate mandate — and need access, judgment, and execution to turn opportunity into commercial outcomes.
I work with a limited number of partners where my network, operator experience, and commercial execution can create measurable value.
Start a conversation →